Literature DB >> 7342320

Surveillance of dengue hemorrhagic fever cases in Thailand.

P Gunakasem, C Chantrasri, S Chaiyanun, P Simasathien, S Jatanasen, V Sangpetchsong.   

Abstract

A long-term surveillance system is necessary for planning and evaluation of hemorrhagic fever control Dry blood collection and using one dengue 2 antigen have been proved to be an efficient method to detect low and high level of HI antibody, determined to prove dengue infection. The percentage of dengue infection serologically proved from cases reported throughout a 3 year study was 52%. Dengue infected cases were reported outside epidemic period with lowest incidence in January. The majority of dengue proven cases occur at age 6 years. For chikungunya infection, studied in Bangkok metropolis and in this study in 72 provinces shows similar result indicating that chikungunya virus shows no significance in clinical and laboratory study in the surveillance programme. This study provides definite information for the planning and evaluation of hemorrhagic fever control.

Entities:  

Mesh:

Year:  1981        PMID: 7342320

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  3 in total

1.  Dengue fever epidemic potential as projected by general circulation models of global climate change.

Authors:  J A Patz; W J Martens; D A Focks; T H Jetten
Journal:  Environ Health Perspect       Date:  1998-03       Impact factor: 9.031

2.  Forecasting disease risk for increased epidemic preparedness in public health.

Authors:  M F Myers; D J Rogers; J Cox; A Flahault; S I Hay
Journal:  Adv Parasitol       Date:  2000       Impact factor: 3.870

3.  The study transplacental chikungunya virus antibody kinetics, Thailand.

Authors:  Veerachai Watanaveeradej; Timothy P Endy; Sriluck Simasathien; Angkool Kerdpanich; Napuschon Polprasert; Chanchai Aree; David W Vaughn; Ananda Nisalak
Journal:  Emerg Infect Dis       Date:  2006-11       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.